Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 89 entries
Sorted by: Best Match Show Resources per page
Idiopathic low-flow priapism in prepuberty: a case report and a review of literature.

Advances in urology

Hekal IA, Meuleman EJ.
PMID: 18827893
Adv Urol. 2008;549861. doi: 10.1155/2008/549861.

Introduction. The incidence of priapism in adults is higher than in children. Although approximately 50% of all episodes of priapism are thought to be idiopathic, there are a number of known specific causes of this disorder. In adults intracavernous...

Cite
Hekal IA, Meuleman EJ. Idiopathic low-flow priapism in prepuberty: a case report and a review of literature. Adv Urol. 2008;549861doi: 10.1155/2008/549861.
Hekal, I. A., & Meuleman, E. J. (2008). Idiopathic low-flow priapism in prepuberty: a case report and a review of literature. Advances in urology, 549861. https://doi.org/10.1155/2008/549861
Hekal, Ihab A, and Meuleman, Eric J H. "Idiopathic low-flow priapism in prepuberty: a case report and a review of literature." Advances in urology vol. (2008): 549861. doi: https://doi.org/10.1155/2008/549861
Hekal IA, Meuleman EJ. Idiopathic low-flow priapism in prepuberty: a case report and a review of literature. Adv Urol. 2008;549861. doi: 10.1155/2008/549861. PMID: 18827893; PMCID: PMC2556090.
Copy Download .nbib Format: NLM
Effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats.

Asian Pacific journal of tropical medicine

Cai WY, Gu YY, Li AM, Cui HQ, Yao Y.
PMID: 25441991
Asian Pac J Trop Med. 2014 Nov;7(11):900-4. doi: 10.1016/S1995-7645(14)60157-7. Epub 2014 Oct 22.

OBJECTIVE: To observe effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats.METHODS: A total of 75 SD rats were randomly divided into A, B, C, D, E groups with 15 in each group. Rats...

Cite
Cai WY, Gu YY, Li AM, et al. Effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats. Asian Pac J Trop Med. 2014;7(11):900-4doi: 10.1016/S1995-7645(14)60157-7.
Cai, W. Y., Gu, Y. Y., Li, A. M., Cui, H. Q., & Yao, Y. (2014). Effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats. Asian Pacific journal of tropical medicine, 7(11), 900-4. https://doi.org/10.1016/S1995-7645(14)60157-7
Cai, Wei-Yan, et al. "Effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats." Asian Pacific journal of tropical medicine vol. 7,11 (2014): 900-4. doi: https://doi.org/10.1016/S1995-7645(14)60157-7
Cai WY, Gu YY, Li AM, Cui HQ, Yao Y. Effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats. Asian Pac J Trop Med. 2014 Nov;7(11):900-4. doi: 10.1016/S1995-7645(14)60157-7. Epub 2014 Oct 22. PMID: 25441991.
Copy Download .nbib Format: NLM
Physical Compatibility of Alprostadil with Commonly Used IV Solutions and Medications in the Neonatal Intensive Care Unit.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Dice JE.
PMID: 23115539
J Pediatr Pharmacol Ther. 2006 Oct;11(4):233-6. doi: 10.5863/1551-6776-11.4.233.

OBJECTIVE: To determine the physical compatibility of alprostadil with intravenous (IV) solutions, a parenteral nutrition (PN) solution, and other intravenous medications commonly used in the neonatal intensive care unit (NICU).METHODS: To simulate y-site administration, each IV solution and the...

Cite
Dice JE. Physical Compatibility of Alprostadil with Commonly Used IV Solutions and Medications in the Neonatal Intensive Care Unit. J Pediatr Pharmacol Ther. 2006;11(4):233-6doi: 10.5863/1551-6776-11.4.233.
Dice, J. E. (2006). Physical Compatibility of Alprostadil with Commonly Used IV Solutions and Medications in the Neonatal Intensive Care Unit. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 11(4), 233-6. https://doi.org/10.5863/1551-6776-11.4.233
Dice, James E. "Physical Compatibility of Alprostadil with Commonly Used IV Solutions and Medications in the Neonatal Intensive Care Unit." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 11,4 (2006): 233-6. doi: https://doi.org/10.5863/1551-6776-11.4.233
Dice JE. Physical Compatibility of Alprostadil with Commonly Used IV Solutions and Medications in the Neonatal Intensive Care Unit. J Pediatr Pharmacol Ther. 2006 Oct;11(4):233-6. doi: 10.5863/1551-6776-11.4.233. PMID: 23115539; PMCID: PMC3468106.
Copy Download .nbib Format: NLM
Effect of hyperbaric oxygen combined with alprostadil in the treatment of elderly diabetic nephropathy and effects on serum miR-126 and miR-342 levels.

Pakistan journal of pharmaceutical sciences

Xi W, Zhou Y, Han X, Yang X.
PMID: 34602388
Pak J Pharm Sci. 2021 May;34(3):1187-1193.

This study aims to investigate the effect of hyperbaric oxygen combined with alprostadil in the treatment of elderly diabetic nephropathy (DN) and its effect on serum miR-126 and miR-342 levels. The total effective rate of the study group was...

Cite
Xi W, Zhou Y, Han X, et al. Effect of hyperbaric oxygen combined with alprostadil in the treatment of elderly diabetic nephropathy and effects on serum miR-126 and miR-342 levels. Pak J Pharm Sci. 2021;34(3):1187-1193
Xi, W., Zhou, Y., Han, X., & Yang, X. (2021). Effect of hyperbaric oxygen combined with alprostadil in the treatment of elderly diabetic nephropathy and effects on serum miR-126 and miR-342 levels. Pakistan journal of pharmaceutical sciences, 34(3), 1187-1193.
Xi, Wei, et al. "Effect of hyperbaric oxygen combined with alprostadil in the treatment of elderly diabetic nephropathy and effects on serum miR-126 and miR-342 levels." Pakistan journal of pharmaceutical sciences vol. 34,3 (2021): 1187-1193.
Xi W, Zhou Y, Han X, Yang X. Effect of hyperbaric oxygen combined with alprostadil in the treatment of elderly diabetic nephropathy and effects on serum miR-126 and miR-342 levels. Pak J Pharm Sci. 2021 May;34(3):1187-1193. PMID: 34602388.
Copy Download .nbib Format: NLM
Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study.

International journal of impotence research

Garrido-Abad P, Senra-Bravo I, Manfredi C, Fernández-Pascual E, Linares-Espinós E, Fernández-Arjona M, Varillas-Delgado D, Martínez-Salamanca JI.
PMID: 33483603
Int J Impot Res. 2021 Jan 22; doi: 10.1038/s41443-020-00400-9. Epub 2021 Jan 22.

Phosphodiesterase type 5 inhibitors (PDE5Is) are the first-line therapeutic option for erectile dysfunction (ED), while second-line therapy includes the alprostadil. Due to the different pharmacodynamic mechanism of PDE5Is and alprostadil, a synergistic action is conceivable when they are administered...

Cite
Garrido-Abad P, Senra-Bravo I, Manfredi C, et al. Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. Int J Impot Res. 2021;doi: 10.1038/s41443-020-00400-9.
Garrido-Abad, P., Senra-Bravo, I., Manfredi, C., Fernández-Pascual, E., Linares-Espinós, E., Fernández-Arjona, M., Varillas-Delgado, D., & Martínez-Salamanca, J. I. (2021). Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. International journal of impotence research, . https://doi.org/10.1038/s41443-020-00400-9
Garrido-Abad, Pablo, et al. "Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study." International journal of impotence research vol. (2021). doi: https://doi.org/10.1038/s41443-020-00400-9
Garrido-Abad P, Senra-Bravo I, Manfredi C, Fernández-Pascual E, Linares-Espinós E, Fernández-Arjona M, Varillas-Delgado D, Martínez-Salamanca JI. Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. Int J Impot Res. 2021 Jan 22; doi: 10.1038/s41443-020-00400-9. Epub 2021 Jan 22. PMID: 33483603.
Copy Download .nbib Format: NLM
Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease.

European urology

Reddy R, Diaz P, Ramasamy R.
PMID: 34772548
Eur Urol. 2022 Jan;81(1):120-121. doi: 10.1016/j.eururo.2021.10.024. Epub 2021 Nov 10.

No abstract available.

Cite
Reddy R, Diaz P, Ramasamy R. Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease. Eur Urol. 2021;81(1):120-121doi: 10.1016/j.eururo.2021.10.024.
Reddy, R., Diaz, P., & Ramasamy, R. (2022). Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease. European urology, 81(1), 120-121. https://doi.org/10.1016/j.eururo.2021.10.024
Reddy, Rohit, et al. "Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease." European urology vol. 81,1 (2022): 120-121. doi: https://doi.org/10.1016/j.eururo.2021.10.024
Reddy R, Diaz P, Ramasamy R. Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease. Eur Urol. 2022 Jan;81(1):120-121. doi: 10.1016/j.eururo.2021.10.024. Epub 2021 Nov 10. PMID: 34772548.
Copy Download .nbib Format: NLM
The prophylactic effect of alprostadil on contrast-induced nephropathy in renal insufficiency patients after percutaneous coronary intervention.

American journal of translational research

Liu D, Gao F, Li L, Jian X, Xiao B.
PMID: 34017563
Am J Transl Res. 2021 Apr 15;13(4):3766-3772. eCollection 2021.

OBJECTIVES: This study explored and analyzed the prophylactic effect of Alprostadil on contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in patients with renal insufficiency.METHODS: From June 2014 to June 2017, 156 patients with coronary artery disease and renal...

Cite
Liu D, Gao F, Li L, et al. The prophylactic effect of alprostadil on contrast-induced nephropathy in renal insufficiency patients after percutaneous coronary intervention. Am J Transl Res. 2021;13(4):3766-3772
Liu, D., Gao, F., Li, L., Jian, X., & Xiao, B. (2021). The prophylactic effect of alprostadil on contrast-induced nephropathy in renal insufficiency patients after percutaneous coronary intervention. American journal of translational research, 13(4), 3766-3772.
Liu, Dongling, et al. "The prophylactic effect of alprostadil on contrast-induced nephropathy in renal insufficiency patients after percutaneous coronary intervention." American journal of translational research vol. 13,4 (2021): 3766-3772.
Liu D, Gao F, Li L, Jian X, Xiao B. The prophylactic effect of alprostadil on contrast-induced nephropathy in renal insufficiency patients after percutaneous coronary intervention. Am J Transl Res. 2021 Apr 15;13(4):3766-3772. eCollection 2021. PMID: 34017563; PMCID: PMC8129369.
Copy Download .nbib Format: NLM
Sexual rehabilitation with intracavernous alprostadil after radical prostatectomy: Outcomes from a nursing program.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica

Gromicho A, Costa P, Araújo D, Pereira D, Ferraz L.
PMID: 34933528
Arch Ital Urol Androl. 2021 Dec 20;93(4):404-407. doi: 10.4081/aiua.2021.4.404.

INTRODUCTION AND OBJECTIVES: Erectile dysfunction (ED) is a common complication after radical prostatectomy that affects quality of life. There are several therapeutic options, including intracavernous alprostadil injections (IAI). However, no specific recommendations have been made on the optimal rehabilitation...

Cite
Gromicho A, Costa P, Araújo D, et al. Sexual rehabilitation with intracavernous alprostadil after radical prostatectomy: Outcomes from a nursing program. Arch Ital Urol Androl. 2021;93(4):404-407doi: 10.4081/aiua.2021.4.404.
Gromicho, A., Costa, P., Araújo, D., Pereira, D., & Ferraz, L. (2021). Sexual rehabilitation with intracavernous alprostadil after radical prostatectomy: Outcomes from a nursing program. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 93(4), 404-407. https://doi.org/10.4081/aiua.2021.4.404
Gromicho, Alexandre, et al. "Sexual rehabilitation with intracavernous alprostadil after radical prostatectomy: Outcomes from a nursing program." Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica vol. 93,4 (2021): 404-407. doi: https://doi.org/10.4081/aiua.2021.4.404
Gromicho A, Costa P, Araújo D, Pereira D, Ferraz L. Sexual rehabilitation with intracavernous alprostadil after radical prostatectomy: Outcomes from a nursing program. Arch Ital Urol Androl. 2021 Dec 20;93(4):404-407. doi: 10.4081/aiua.2021.4.404. PMID: 34933528.
Copy Download .nbib Format: NLM
An unusual migratory polycyclic eruption after administration of prostaglandin E in a neonate.

JAAD case reports

Young GJ, Harter N, Luu M.
PMID: 27752529
JAAD Case Rep. 2016 Oct 06;2(5):377-379. doi: 10.1016/j.jdcr.2016.08.001. eCollection 2016 Sep.

No abstract available.

Cite
Young GJ, Harter N, Luu M. An unusual migratory polycyclic eruption after administration of prostaglandin E in a neonate. JAAD Case Rep. 2016;2(5):377-379doi: 10.1016/j.jdcr.2016.08.001.
Young, G. J., Harter, N., & Luu, M. (2016). An unusual migratory polycyclic eruption after administration of prostaglandin E in a neonate. JAAD case reports, 2(5), 377-379. https://doi.org/10.1016/j.jdcr.2016.08.001
Young, Grace J, et al. "An unusual migratory polycyclic eruption after administration of prostaglandin E in a neonate." JAAD case reports vol. 2,5 (2016): 377-379. doi: https://doi.org/10.1016/j.jdcr.2016.08.001
Young GJ, Harter N, Luu M. An unusual migratory polycyclic eruption after administration of prostaglandin E in a neonate. JAAD Case Rep. 2016 Oct 06;2(5):377-379. doi: 10.1016/j.jdcr.2016.08.001. eCollection 2016 Sep. PMID: 27752529; PMCID: PMC5061299.
Copy Download .nbib Format: NLM
Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation.

Sexual medicine

Goldstein SW, Gonzalez JR, Gagnon C, Goldstein I.
PMID: 27090169
Sex Med. 2016 Sep;4(3):e166-75. doi: 10.1016/j.esxm.2016.03.026. Epub 2016 Apr 15.

INTRODUCTION: Female sexual arousal disorder is a pathophysiologic state characterized clinically by persistent or recurrent inability to attain or maintain an adequate lubrication-swelling response of sexual excitement until completion of sexual activity. Prior clinical experience with alprostadil products for...

Cite
Goldstein SW, Gonzalez JR, Gagnon C, et al. Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation. Sex Med. 2016;4(3):e166-75doi: 10.1016/j.esxm.2016.03.026.
Goldstein, S. W., Gonzalez, J. R., Gagnon, C., & Goldstein, I. (2016). Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation. Sexual medicine, 4(3), e166-75. https://doi.org/10.1016/j.esxm.2016.03.026
Goldstein, Sue W, et al. "Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation." Sexual medicine vol. 4,3 (2016): e166-75. doi: https://doi.org/10.1016/j.esxm.2016.03.026
Goldstein SW, Gonzalez JR, Gagnon C, Goldstein I. Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation. Sex Med. 2016 Sep;4(3):e166-75. doi: 10.1016/j.esxm.2016.03.026. Epub 2016 Apr 15. PMID: 27090169; PMCID: PMC5005296.
Copy Download .nbib Format: NLM
Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2.

Jornal vascular brasileiro

Manhanelli MAB, Duarte EG, Mariuba JVO, Linardi F, Costa JA, Gali JC, Yoshida WB, Gali JC.
PMID: 34211521
J Vasc Bras. 2020 Nov 30;19:e20200072. doi: 10.1590/1677-5449.200072.

The current coronavirus pandemic has already taken a great toll globally, causing massive morbidity and mortality. One of its severe forms is a thrombophilic state that can damage several systems. This article reports the case of 60-year-old female patient...

Cite
Manhanelli MAB, Duarte EG, Mariuba JVO, et al. Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2. J Vasc Bras. 2020;19:e20200072doi: 10.1590/1677-5449.200072.
Manhanelli, M. A. B., Duarte, E. G., Mariuba, J. V. O., Linardi, F., Costa, J. A., Gali, J. C., Yoshida, W. B., & Gali, J. C. (2020). Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2. Jornal vascular brasileiro, 19e20200072. https://doi.org/10.1590/1677-5449.200072
Manhanelli, Marcos Antonio Bonacorso, et al. "Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2." Jornal vascular brasileiro vol. 19 (2020): e20200072. doi: https://doi.org/10.1590/1677-5449.200072
Manhanelli MAB, Duarte EG, Mariuba JVO, Linardi F, Costa JA, Gali JC, Yoshida WB, Gali JC. Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2. J Vasc Bras. 2020 Nov 30;19:e20200072. doi: 10.1590/1677-5449.200072. PMID: 34211521; PMCID: PMC8218011.
Copy Download .nbib Format: NLM
Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease.

European urology

Reddy R, Diaz P, Ramasamy R.
PMID: 34772548
Eur Urol. 2021 Nov 09; doi: 10.1016/j.eururo.2021.10.024. Epub 2021 Nov 09.

No abstract available.

Cite
Reddy R, Diaz P, Ramasamy R. Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease. Eur Urol. 2021;doi: 10.1016/j.eururo.2021.10.024.
Reddy, R., Diaz, P., & Ramasamy, R. (2021). Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease. European urology, . https://doi.org/10.1016/j.eururo.2021.10.024
Reddy, Rohit, et al. "Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease." European urology vol. (2021). doi: https://doi.org/10.1016/j.eururo.2021.10.024
Reddy R, Diaz P, Ramasamy R. Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease. Eur Urol. 2021 Nov 09; doi: 10.1016/j.eururo.2021.10.024. Epub 2021 Nov 09. PMID: 34772548.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 89 entries